Additional Indication Programs and Further Indication Programs. Subject to the terms and conditions of this Agreement (including [Section 3.3(b)(i)] and [Section 3.3(b)(ii)]), with respect to each Additional Indication Program or Further Indication Program and effective as of the exercise by Takeda of the applicable Additional Indication License Option or Further Indication License Option, Poseida hereby grants to Takeda an exclusive, royalty-bearing license, with the right to grant sublicenses to Affiliates and Third Parties (through multiple tiers), under the Licensed IP and Poseida’s interest in the Joint Arising IP to Exploit any and all Selected Candidates and Licensed Products under such Additional Indication Program or Further Indication Program in the Territory in the Field.
“Initiation” means, with respect to a given Clinical Trial, the administration of the first dose of a Licensed Product to the first subject in such Clinical Trial in accordance with the protocol for such Clinical Trial. Cognates of the word “Initiation” will have correlative meanings.
Additional Indication Programs. Takeda shall have the right to select Indications, in accordance with [Section 3.3(c)], for up to four (4) additional programs (each an “Additional Indication Program”) at any time not later than [……], as such period may be extended pursuant to Section 3.1(b) (the “Additional Indication Option Period”). Takeda shall have the right to exercise its option (the “Additional Indication License Option”) by providing written notice of such election to Poseida (“Additional Indication Program Notice”) at any time after the Effective Date and prior to the end of the Additional Indication Option Period. Upon exercising the Additional Indication License Option and Poseida’s receipt of the Additional Indication Program Notice, Takeda shall be deemed to have entered into the license set forth in [Section 5.2(c)]. [……].
Additional Indication Programs. As partial consideration for the exclusive rights and covenants granted by Poseida to Takeda pursuant to this Agreement, within [……] after Takeda’s selection of an Indication for an Additional Indication Program, Takeda shall make to Poseida a one-time non-refundable, non-creditable payment of [……] for each such Additional Indication Program. In no event will the total amount of option exercise payments for the Additional Indication Programs exceed [……].
Further Indication Programs. Takeda shall have the right to select Indications, in accordance with [Section 3.3(c)], for up to two (2) further Programs (each a “Further Indication Program”) at any time not later than [……], as such period may be extended pursuant to Section 3.1(b) (the “Further Indication Option Period”). Takeda shall have the right to exercise its option (the “Further Indication License Option”) by providing written notice of such election to Poseida (“Further Indication Program Notice”) at any time after the Effective Date and prior to the end of the Further Indication Option Period. Upon exercising the Further Indication License Option and Poseida’s receipt of the Further Indication Program Notice, Takeda shall be deemed to have entered into the license set forth in [Section 5.2(c)]. [……].
Initial Indication Programs. Subject to the terms and conditions of this Agreement, with respect to each Initial Indication Program, Poseida hereby grants to Takeda an exclusive, royalty-bearing license, with the right to grant sublicenses to Affiliates and Third Parties (through multiple tiers), under the Licensed IP and Poseida’s interest in the Joint Arising IP, to Exploit any and all Selected Candidates and Licensed Products under such Initial Indication Program in the Territory in the Field.
[……] Indications. Takeda may select a [……] Indication for use in an Additional Indication Program, Further Indication Program or as a [……] at any time during the [……] Indication Exclusivity Period. Following the [……] Indication Exclusivity Period, with respect to the Additional Indication Programs and Further Indication Programs, Takeda shall still have the right to [……].
“Program” means each of the Initial Indication Programs, the Additional Indication Programs and the Further Indication Programs, which, for clarity, shall continue for the Term of this Agreement or until terminated by Takeda.
Takeda has initiated and elected to initiate, respectively, [……] programs for the Indications of # hemophilia A and # [……] (each an “Initial Indication Program” and together, the “Initial Indication Programs”). Pursuant to the terms of this Agreement and as further provided in this ARTICLE III, each Party shall use Commercially Reasonable Efforts to carry out the activities assigned to it as specified in the applicable Research Plan through Candidate Selection. [……].
Further Indication Programs. As partial consideration for the exclusive rights and covenants granted by Poseida to Takeda pursuant to this Agreement, within [……] after Takeda’s selection of an Indication for a Further Indication Program, Takeda shall make to Poseida a one-time non-refundable, non-creditable payment of [……] for each such Further Indication Program. In no event will the total amount of option
AllDrafts is a cloud-based editor designed specifically for contracts. With automatic formatting, a massive clause library, smart redaction, and insanely easy templates, it’s a welcome change from Word.
And AllDrafts generates clean Word and PDF files from any draft.